Introduction
The use of thiazides for treating arterial hypertension has been criticised. The arguments have been that thiazides do not reduce excess mortality, do not reduce the incidence of myocardial infarction, increase known risk factors, and produce more adverse effects than previously realised. As no treatment has yet shown a clear reduction in mortality or morbidity from acute myocardial infarction interest has focused on the risk factors and adverse effects. Evidence against thiazides was substantiated by a Medical Research Council trial, which compared treatment with a fixed dose of bendrofluazide (10 mg/day) or a titrated dose of propranolol with placebo. There was no basis for choosing a dose of 10 mg bendrofluazide.
We investigated the relevant dose range of bendrofluazide for treating mild to moderate arterial hypertension as this could affect both the choice and outcome of treatment.
Methods
Selection ofpatients-Patients aged 25-70 presenting to general practices in Zealand, Denmark, with newly diagnosed or previously treated arterial hypertension (up to two drugs) who gave informed consent were eligible for the study.
Patients were excluded if they were pregnant or lactating; had had a myocardial infarction or stroke within the past six months; had angina pectoris; were being treated for heart failure, gout, or uncontrolled diabetes mellitus or with drugs that reduced lipid concentrations; were intolerant of bendrofluazide; had reduced kidney function (creatinine concentration >150 [tmol/l); did not take 80-120% of the prescribed tablets while receiving a placebo at the start of the study.
Study design-Patients whose blood pressure was between 100 and 120 mm Hg after they had taken placebo for six weeks were randomly allocated in blocks of 10 on a double blind basis to receive placebo or bendrofluazide at a dose of 1 25, 2-5, 5, or 10 mg a day. Randomisation was performed from a list of computer generated numbers. The 10 mg dose was chosen because this was used in the Medical Research Council's trial and the 2 5 and 5 mg doses because they are recommended by the joint national committee on detection, evaluation, and treatment of high blood pressure.' The dose of 1 25 mg was believed to represent a point on the lower part of the dose-response curve. The active tablets contained 573 mg potassium chloride and either 1 25 mg or 2-5 mg bendrofluazide (Centyl K, Leo Pharmaceutical Products). Placebo and active tablets were identical in appearance and taste. All patients received four tablets daily, two in the morning and two at lunch. Those receiving fewer than four active tablets daily were given the active tablets in the morning. Patients were assessed on an outpatient basis for four, 10 , and 12 weeks after randomisation. Biochemical variables were measured before randomisation and at the end of the study; these variables included total cholesterol, apolipoprotein A I, apolipoprotein B, sodium, potassium, glucose, fructosamine, urate, and creatinine concentrations. The study was approved by the local ethical committee.
Methods ofassessment-The patient's blood pressures were measured twice, in the sitting position after five minutes' rest, with a random zero sphygmomanometer (Hawksley) and a Tricuff. Diastolic blood pressure was taken at the point where Korotkoff sounds disappeared (phase V). Three trained nurses took all the blood pressure measurements. Heart rate was assessed by counting the radial pulse. At each visit patients were asked about adverse effects. All biochemical analyses were carried out in a high quality automated laboratory (CALAB, Stockholm, Sweden).
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We Discussion Drug trials should not be conducted without knowing the relevant dose.' Hypertension is treated to prevent mortality and morbidity, and an ideal doseresponse study should establish the relation between the dose and the reduction in mortality and morbidity. Obviously, such studies are not feasible so the relation between the dose and the antihypertensive effect is usually studied. The dose that lowers the blood pressure most does not necessarily have the greatest effect on mortality and morbidity.
When deciding on the dose for clinical use it is necessary to strike a balance between unwanted and wanted effects. Several antihypertensive drugs have been introduced with too high doses. Both the number and the severity of adverse effects can be reduced by using smaller doses without affecting the efficacy.
Thiazides are used to treat several conditions, and the optimal dose for each condition is not the same, as was assumed in early studies. 6 Knowledge of the time course of wanted and unwanted effects with all doses is important. Constructing dose-response curves before the full effect is obtained shifts the curve to the right and reduces the apparent efficacy. We measured blood pressures after three months of treatment, when both blood pressure and biochemical effects should have stabilised.i' If measurements had been taken earlier the antihypertensive effect of the 1 25 mg dose would not have been seen as it occurred slowly. The method of expressing the effect ofantihypertensive drugs (in absolute figures, as a percentage reduction in blood pressure, or by number of responders) did not affect the conclusion.
Hypertensive patients who do not respond to thiazides are characterised by activation of the reninangiotensin system and increased aldosterone concentrations. " Thus biochemical effects may differ between responders and non-responders. We found no such differences.
Increasing the dose of bendrofluazide increases the adverse biochemical effects but not hypertensive activity. Thiazides have been criticised mainly for their biochemical effects,'2B2 but bendrofluazide at a dose of 1 25 mg caused only one relevant effect (a 6% increase in urate concentration). Thus much of the criticism of thiazides is based on use of too high doses.
Hypokalaemia induced by thiazides seems not to cause arrhythmias as was previously thought,"4' but limiting hypokalaemia must be beneficial. A substudy of the Medical Research Council's trial found no benefit in potassium supplementation.'6 Thus giving potassium with the bendrofluazide may not have been important. We found that the decrease in potassium concentration was mainly related to the dose of thiazide.
Thiazides are known to impair glucose tolerance." We found a clear correlation between the dose and an increase in fasting glucose concentrations, but only the 10 mg dose gave a significant effect. Recently the same effect was reported for hydrochlorothiazide at an average dose of 40 mg a day. ' Recently, interest has focused on adverse effects of hypertensive drugs on lipid profiles. 19 20 Numerous studies have shown that diuretics adversely alter lipoprotein metabolism at least during short term trials, but this was found with high doses compared with the dose suggested by this study. It is unknown whether the effect on lipoprotein metabolism is related to dose. 1 ' 20 We showed clear relations between the dose of bendrofluazide and both total cholesterol and apolipoprotein B concentrations, which were consistent with the results of other studies. '8 20 We therefore conclude that the adverse effect of diuretics on lipoprotein metabolism is related to dose and could be avoided by prescribing lower doses. When evaluating comparative trials between thiazides and newer treatments it is important to be aware of the drug doses. A recent report claimed that captopril has less effect on glucose and lipoprotein metabolism than hydrochlorothiazide.' The dose of hydrochlorothiazide was on average 40 (SD 12) mg, and thus more than 60% of the patients received an unrealistically high dose, creating a bias in favour of captopril.
Thiazides have been suggested to increase mortality and morbidity from acute myocardial infarction due to their effects on lipids.2' Re-evaluation of the data does not confirm this, and several trials have found that thiazides do not alter mortality and morbidity.2 22 2' The antihypertensive effect of thiazides may decrease the risk of acute myocardial infarction, but this is counteracted by increases in total and low density lipoprotein cholesterol concentrations. If the adverse lipid profile is considered' important our findings suggest that new mortality studies using correct doses of thiazide should be performed.
The Medical Research Council's trial found an unexpectedly high number of subjective adverse effects.' Our study, although indicating that increasing the dose increases the number of adverse effects, was too small to be conclusive on this problem. A Medical Research Council substudy, which compared 5 and 10 mg bendrofluazide daily, found fewer adverse effects in the low dose group,'5 as did a long term trial of the 5 mg dose.s We found that the number of adverse effects in the group given 1 25 mg was the same as that in the group given placebo, although the effects were different. Patients' symptoms are known to change when they receive antihypertensive treatment. We conclude that in low doses thiazides are one of the most effective and well tolerated treatments for arterial hypertension. 
